Updates
** Shares of vaccine makers rise after FDA leaders' comments on new guidelines for approval of COVID boosters
** Shares of Moderna MRNA.O up 8.5% at $28.62, Pfizer PFE.N up 2.2% at $23.50 and Novavax NVAX.O up 1.5% at $7.86
** U.S. FDA plans to mandate new placebo-controlled clinical trials for approval of annual COVID boosters for Americans under 65 in good health
** For adults over the age of 65 years, data, FDA can approve based on data from tests that measure immune response in patients
** "In the big picture this actually eases some investor concern for 2025 guidance to some extent," Jefferies analyst Michael Yee says
** FDA advisers also scheduled to discuss on Thursday whether to recommend COVID-19 vaccines for 2025-26 for targeting the LP.8.1 subvariant
** LP.8.1 strain is spreading faster than other variants, becoming dominant in different parts of the world, including the U.S. and Europe
** Including session's moves, MRNA down 31.6%, PFE down 11.5% and NVAX down 2.9% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。